NO20050902L - Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier - Google Patents

Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier

Info

Publication number
NO20050902L
NO20050902L NO20050902A NO20050902A NO20050902L NO 20050902 L NO20050902 L NO 20050902L NO 20050902 A NO20050902 A NO 20050902A NO 20050902 A NO20050902 A NO 20050902A NO 20050902 L NO20050902 L NO 20050902L
Authority
NO
Norway
Prior art keywords
related compounds
angiogenic therapies
compounds
tetrapropylammonium tetrathiomolybdate
tetrathiomolybdate
Prior art date
Application number
NO20050902A
Other languages
English (en)
Norwegian (no)
Inventor
George J Brewer
Sofia D Merajver
Dimitri Coucouvanis
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of NO20050902L publication Critical patent/NO20050902L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20050902A 2002-07-23 2005-02-18 Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier NO20050902L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39780402P 2002-07-23 2002-07-23
PCT/US2003/022914 WO2004009072A2 (fr) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate et composes associes pour therapies anti-angiogeniques

Publications (1)

Publication Number Publication Date
NO20050902L true NO20050902L (no) 2005-04-19

Family

ID=30771119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050902A NO20050902L (no) 2002-07-23 2005-02-18 Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier

Country Status (16)

Country Link
US (1) US7888389B2 (fr)
EP (1) EP1539131A4 (fr)
JP (1) JP2005538093A (fr)
KR (1) KR20050025976A (fr)
CN (1) CN1688303A (fr)
AU (1) AU2003261222B2 (fr)
BR (1) BR0312845A (fr)
CA (1) CA2493341A1 (fr)
EA (1) EA008683B1 (fr)
GE (1) GEP20074270B (fr)
IL (1) IL166385A0 (fr)
MX (1) MXPA05000875A (fr)
NO (1) NO20050902L (fr)
NZ (1) NZ537896A (fr)
WO (1) WO2004009072A2 (fr)
ZA (1) ZA200501162B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
CN1324234A (zh) * 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
EP2500018B1 (fr) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Prévention et/ou traitement des maladies cardio-vasculaires et/ou insuffisances cardiaques associées
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
CA2493341A1 (fr) 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate et composes associes pour therapies anti-angiogeniques
CA2496411A1 (fr) 2002-08-20 2004-03-04 Protemix Corporation Limited Formes posologiques et traitements s'y rapportant
RU2002128364A (ru) * 2002-10-23 2004-04-27 Институт нефтехимического синтеза РАН им. А.В. Топчиева Способ получения присадки к смазочным материалам (варианты)
CA2527236A1 (fr) * 2003-05-27 2004-12-23 Attenuon Llc Analogues de thiotungstate et leurs utilisations
EP1729784A1 (fr) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations de composés de thiomolybdate ou de thiotungstate et leurs utilisations
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
AU2005281353A1 (en) 2004-07-19 2006-03-16 Philera New Zealand Limited Synthesis of triethylenetetramines
US20060134708A1 (en) * 2004-10-14 2006-06-22 Northwestern University Detection and treatment of renal cancer
WO2008103421A1 (fr) * 2007-02-21 2008-08-28 Ssv Therapeutics, Inc. Adamantanamines et sels de néramexane d'acides thiomolybdiques et thiotungsténiques
WO2009009622A2 (fr) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Compositions pharmaceutiques contenant du attm, procédés pour obtenir et conserver le cuivre à un état ciblé et stable et pour prévenir et traiter des maladies du système central nerveux liées au cuivre
US20100312139A1 (en) * 2009-06-04 2010-12-09 Board Of Regents Of The University Of Texas System Method for Identifying Mammals at Risk for Elevated intracranial Pressure
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
CN107530311A (zh) 2015-02-03 2018-01-02 卡德门制药有限公司 稳定的曲恩汀制剂
AU2018379255A1 (en) * 2017-12-04 2020-06-25 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4225386A1 (fr) 2020-10-07 2023-08-16 CTI Vascular AG Dispositifs bioactivables et procédés associés

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4343746A (en) 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US4430443A (en) 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
US4766226A (en) 1984-02-01 1988-08-23 Smithkline Beckman Corporation Antitumor pharmaceutical compositions and methods for treating tumors employing α,ω-bis(disubstitutedphosphino)hydrocarbon derivatives or [α, ω-bis(disubstitutedphosphino)hydrocarbon] di
JPS62501769A (ja) 1984-12-18 1987-07-16 デイビツト　ラビン 細胞毒性アルデヒドとベニシラミンとの反応性成物を含有する抗腫瘍組成物及びその使用方法
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4604278A (en) * 1985-05-17 1986-08-05 Gte Products Corporation Production of ammonium tetrathiomolybdate
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
MX172248B (es) 1989-12-20 1993-12-09 Univ Mexico Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
CA2138538A1 (fr) 1992-06-19 1994-01-06 Dimitris Skalkos Production et utilisation d'imines de la porphyrine
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
NZ304285A (en) 1995-03-14 1998-12-23 Siemens Ag Ultrasonic atomizer device with a removable precision dosing unit
US5950619A (en) 1995-03-14 1999-09-14 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
EP1234585A3 (fr) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Compositions pour la prévention ou le traitement du cancer
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
JP2002524426A (ja) 1998-09-04 2002-08-06 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 癌の予防または処置のための方法および組成物
EP1471931A4 (fr) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst Export non traditionnel de cytokines pro-inflammatoires dependant du cuivre et methodes, compositions et kits associes
CA2490541A1 (fr) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Traitement reduisant le taux de cuivre pour des maladies inflammatoires et fibreuses
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
CA2493341A1 (fr) 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate et composes associes pour therapies anti-angiogeniques

Also Published As

Publication number Publication date
CA2493341A1 (fr) 2004-01-29
EP1539131A4 (fr) 2009-07-08
MXPA05000875A (es) 2005-09-30
NZ537896A (en) 2007-12-21
US20040259945A1 (en) 2004-12-23
EA200500244A1 (ru) 2005-12-29
EP1539131A2 (fr) 2005-06-15
US7888389B2 (en) 2011-02-15
AU2003261222A1 (en) 2004-02-09
WO2004009072A3 (fr) 2004-04-08
KR20050025976A (ko) 2005-03-14
BR0312845A (pt) 2005-06-07
ZA200501162B (en) 2005-09-05
WO2004009072A2 (fr) 2004-01-29
IL166385A0 (en) 2006-01-16
AU2003261222B2 (en) 2009-07-09
EA008683B1 (ru) 2007-06-29
GEP20074270B (en) 2007-12-25
WO2004009072B1 (fr) 2004-07-08
JP2005538093A (ja) 2005-12-15
CN1688303A (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
NO20050902L (no) Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
WO2004052280A3 (fr) Composes anti-angiogenique et utilisations de ceux-ci dans le traitement du cancer
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
SE0301700D0 (sv) Novel compounds
NO20074446L (no) DR5-antistoffer og anvendelser derav
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
WO2005094384A3 (fr) Procedes et compositions pour le traitement de desequilibres ioniques
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
DK2269656T3 (da) Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20064584L (no) Tetrahydropyridoindolderivater
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2005074598A3 (fr) Composes precurseurs de nitroxyle et methodes d'utilisation
SE0301653D0 (sv) Novel compounds
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application